<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676386</url>
  </required_header>
  <id_info>
    <org_study_id>ALCMI-014</org_study_id>
    <nct_id>NCT04676386</nct_id>
  </id_info>
  <brief_title>Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy</brief_title>
  <acronym>BEACON-LUNG</acronym>
  <official_title>Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addario Lung Cancer Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biodesix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Addario Lung Cancer Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Observational study will explore the utility of the Biodesix, Inc. &quot;PIR&quot; (primary immune&#xD;
      response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor&#xD;
      proportion score (TPS) &gt; 50% and ECOG performance status (PS) 0-2 NSCLC patients who are&#xD;
      treated with PD-1/PD-L1 based therapy with or without the addition of platinum based&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, multicenter study designed to assess biomarkers (serum and plasma)&#xD;
      as predictive of early progression in 390 treatment-naive patients with advanced stage&#xD;
      non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥50% treated with two standard of care (SOC)&#xD;
      regimens, platinum based PD-1/PD-L1 regimen with monotherapy (single agent PD-1/PD-L1&#xD;
      therapy).&#xD;
&#xD;
      Prior to enrollment, tumor specimens will be tested for PD-L1 expression according to&#xD;
      participating centers' standard operating procedures. Patients will be treated, according to&#xD;
      physician choice, with platinum-based PD-1/PD-L1 regimen versus single agent PD-1/PD-L1&#xD;
      regimen. For each treatment cohort of 195 patients, enrollment will proceed in sub-cohorts to&#xD;
      ensure a population with 20% ECOG PS2 patients and a total of 40 squamous cell carcinoma&#xD;
      patients per treatment arm.&#xD;
&#xD;
      Patients will receive one of the following standard-of-care (SOC) treatment regimens at the&#xD;
      discretion of the treating investigator:&#xD;
&#xD;
        -  PD-1/PD-L1 therapy&#xD;
&#xD;
        -  Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination&#xD;
&#xD;
      Tumor assessment will follow RECIST v1.1.&#xD;
&#xD;
      Blood draw for biomarker assessment will be performed at these time-points: pretreatment,&#xD;
      start of 3rd cycle and investigator assessed progression. The biomarker analysis will be&#xD;
      performed retrospectively.&#xD;
&#xD;
      Remaining serum and plasma will be stored for subsequent exploratory studies and will be&#xD;
      available to the investigators in the ALCMI network per ALCMI standard operating procedures.&#xD;
&#xD;
      Additionally, pathology reports including PD-L1 results and Next Generation Sequencing&#xD;
      results, from any CLIA laboratory, will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker PIR evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>To collect biospecimens and evaluate candidate biomarkers of early progression on patients with &gt;50% PD-L1 positive tumors treated with PD-1/PD-L1 monotherapy or PD-1/PD-L1/chemotherapy combination</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">390</enrollment>
  <condition>NSCLC Stage IV</condition>
  <condition>NSCLC, Stage IIIC</condition>
  <arm_group>
    <arm_group_label>PD1/PD-L1</arm_group_label>
    <description>Standard of Care: PD1/PD-L1 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD1/PD-L1 + chemo</arm_group_label>
    <description>Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Primary Immune Response (PIR) test by Biodesix, Inc.</intervention_name>
    <description>Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.</description>
    <arm_group_label>PD1/PD-L1</arm_group_label>
    <arm_group_label>PD1/PD-L1 + chemo</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A maximum of three blood draws will be performed over three years.&#xD;
&#xD;
      Approximately 25 mLs venous blood will be collected into blood collection tubes provided in&#xD;
      the study kit. Blood should be drawn at the time of other clinical laboratories whenever&#xD;
      possible to prevent additional venipuncture or port access, otherwise, a study-specific blood&#xD;
      draw may occur at the time of the standard of care office visit.&#xD;
&#xD;
      Peripheral blood draws may occur on-site or via a remote phlebotomist dispatched by the&#xD;
      enrolling institution. Sites may mail the blood draw kit to the subject prior to arrival of&#xD;
      the remote phlebotomist.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients will be treatment-naïve advanced NSCLC patients with PD-L1 TPS ≥50% who&#xD;
        will receive PD-1/PD-L1 or PD-1/PD-L1 plus pemetrexed/carboplatin or&#xD;
        paclitaxel/nab-paclitaxel/carboplatin and are managed per treating physician's standard of&#xD;
        care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment naïve for their stage IIIC/IV AJCC 8 non-small cell lung cancer with a tumor&#xD;
             biopsy PD-L1 TPS &gt; 50%&#xD;
&#xD;
          -  Intent to treat with PD-1/PD-L1 or PD-1/PD-L1 plus pemetrexed/carboplatin or&#xD;
             paclitaxel/nab-paclitaxel/carboplatin&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Ability to consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the requirements of the protocol or to provide informed consent&#xD;
             is impaired or is unwilling to comply with the protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Addario Lung Cancer Medical Institute (ALCMI)</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryJo Fidler, MD</last_name>
      <phone>312-942-5498</phone>
      <email>rush_research_portal@rush.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

